2705, boulevard Laurier
R-0755
Québec, QC
Canada G1V 4G2
Dernières nouvelles
Information non disponible
- Pillet, StéphaneEmployéCHUL+1 418-525-4444, poste 48799stephane.pillet@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-0709
Québec, QC
Canada G1V 4G2
Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States
Article de revuemedRxiv, 2024.
Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States
Article de revueElife, 13 , 2024.
Specific and off-target immune responses following COVID-19 vaccination with ChAdOx1-S and BNT162b2 vaccines-an exploratory sub-study of the BRACE trial
Article de revueEBioMedicine, 103 , 2024.
The flavonoid quercetin decreases ACE2 and TMPRSS2 expression but not SARS-CoV-2 infection in cultured human lung cells
Article de revueBiofactors, 2024.
Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection
Article de revueJ Virol, 98 (6), 2024.
Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial
Article de revueTrials, 25 (1), 2024.
Kidney organoids reveal redundancy in viral entry pathways during ACE2-dependent SARS-CoV-2 infection
Article de revueJ Virol, 98 (3), 2024.
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
Article de revueEBioMedicine, 92 , 2023.
Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines
Article de revueVaccine, 41 (48), 2023.
Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19
Article de revueMicroorganisms, 11 (8), 2023.
Projets actifs
- Aerosol Infection Research: Better mOdels to Reduce iNdoor Exposure (AIRBORNE), du 2022-06-01 au 2025-05-30
- Chaire d’excellence de recherche du Canada on Biology and Control of Zoonotic and Pandemic Respiratory Viruses, du 2023-09-01 au 2033-05-26
- Fond de démarrage-Nouveau chercheur, du 2024-05-27 au 2027-03-31
- Is treatment with a combination of licensed influenza antivirals superior to monotherapy for highly pathogenic H5N1 influenza virus from cattle?, du 2024-09-01 au 2025-08-31